Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study

Andriyanto, Dwi Ris; Prihantono, Prihantono; Syamsu, Salman Ardi; Kusuma, Muhammad Ihwan; Hendarto, Joko; Indra, .; Smaradania, Nilam; Sampepajung, Elridho; Mappiwali, Asrul

doi:10.1016/j.amsu.2022.103614

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical oophorectomy and ovarian irradiation are two options for treating ovarian ablation. Luteinizing hormone-releasing hormone (LHRH) agonists can be used to inhibit ovarian estrogen synthesis by inhibiting the secretion of the pituitary follicle-stimulating hormone and luteinizing hormone [20] , [21] . In Indonesia, the LHRH agonist drugs available include goserelin and leuprolide, to be administered every 1 or 3 months.…”

Section: Discussionmentioning

confidence: 99%

Synchronous breast cancer and non-Hodgkin lymphoma: A case report

Syamsu

Setiady

Smaradania

et al. 2022

International Journal of Surgery Case Reports

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Synchronous breast cancer and non-Hodgkin lymphoma: A case report

Syamsu

Setiady

Smaradania

et al. 2022

International Journal of Surgery Case Reports

Self Cite

View full text Add to dashboard Cite

Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study

Kurniawan

Ferianto

Pieter

2022

View full text Add to dashboard Cite

BACKGROUND: Breast cancer in Indonesia has continued to increase. One diagnostic modality is immunohistochemical examination to determine breast cancer subtypes. OBJECTIVE: To determine breast cancer metastasis and mortality rates based on molecular subtypes. METHODS: A descriptive study was conducted based on retrospective data from hospital medical records from January 2016 to December 2019. The data comprised age, clinical stage, histopathological grade, molecular subtype, location, metastasis, and breast cancer mortality. The data were processed and analyzed. RESULTS: This study involved 172 patients. The most prevalent breast cancer subtypes were luminal A (60, 34.8%), followed by HER2 (47, 27.4%), triple-negative (38, 22.4%), and luminal B (27, 15.4%). The metastasis rate was 37.21% (64/172), with bone the tissue most affected (32 cases, 50%), followed by lung (24 cases, 37.5%) and liver (8 cases, 12.5%). The highest rates of bone, lung, and liver metastases were subtypes luminal A (31%), HER2 (29%), and triple-negative (38%), respectively. The mortality rate was 21% (36/172), with most in the triple-negative group (28.9%), followed by luminal B (25.9%), HER2 (21.2%), and luminal A (13.3%). CONCLUSIONS: Determination of breast cancer molecular subtypes through immunohistochemistry can determine the level of metastasis and mortality in breast cancer.

show abstract

Role of ovarian suppression in adjuvant treatment of breast cancer

Ruban,

Karagodina,

Bolotina

et al. 2023

Medicinskij alfavit

View full text Add to dashboard Cite

Adjuvant endocrine therapy is an integral component of treatment for resectable luminal breast cancer. Tamoxifen or aromatase inhibitors monotherapy has been the standard of practice for many years. However, recent studies have shown that the addition of ovarian suppression statistically significantly increases survival rates in patients at high risk for recurrence and with poor prognosis factors. In this literature review, we summarized recent data regarding the role of ovarian suppression in adjuvant therapy for hormone-positive breast cancer. Suppression of ovarian function was most effective in young patients (< 35 years) in the premenopausal stage when adverse prognostic factors were present (indications for (neo)adjuvant CT, G3, etc.) The authors noted that using of aromatase inhibitors instead of tamoxifen in this subgroup significantly reduced the risk of breast cancer recurrence. Ovarian suppression, especially in combination with aromatase inhibitors, was accompanied by an increase in the incidence of adverse side effects, particularly osteoporosis and bone fractures, which can be reduced by prescribing adequate accompanying therapy with OMA. The optimal duration of ovarian function suppression has also not been determined, but a two-year course seems optimal, given the results of large clinical trials. In the protocols performed, there was no significant effect of temporary ovarian suppression on the likelihood of subsequent pregnancy.

show abstract

Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study

Cited by 3 publications

References 23 publications

Synchronous breast cancer and non-Hodgkin lymphoma: A case report

Synchronous breast cancer and non-Hodgkin lymphoma: A case report

Evaluation of breast cancer metastasis and mortality rates based on molecular subtype: A description study

Role of ovarian suppression in adjuvant treatment of breast cancer

Contact Info

Product

Resources

About